Safe View Body Bags Launched by Mopec

Safe View body bags by Mopec has been launched. The news was announced today.

Safe View body bags are designed specifically for COVID-19 crisis response. Featuring a transparent inner layer, the Safe View bag allows remains to be viewed with minimal exposure risk to those caring for the deceased.

“Unfortunately, the country continues to face surges of COVID-19, and it’s only a matter of time until we are also in the midst of flu season,” said Jay Troger, CEO of Mopec. “The workers who care for our deceased are often an overlooked sector of public health. They deserve to have adequate supplies of personal protective equipment (PPE) that keep them safe. Mopec’s Safe View body bags are designed to keep these workers safe while humanely caring for decedents.”

The Safe View body bag is the latest addition to Mopec’s Guardian Systems line, which also includes PPE, the patented MERC portable cooling system, eight other varieties of body bags, and the Guardian Rack system for decedent storage.

Additionally, Mopec’s team of experts offers free consultation services to agencies and companies responding to COVID-19. Throughout the pandemic, the company has been working alongside its customers around the country to provide insight and guidance on products and industry trends. With nearly 30 years of experience, Mopec is uniquely prepared to connect health care and government organizations with what they need to serve their community and keep people safe.

“The organizations that handle decedents have a tough job,” said Troger. “Having the right resources and equipment on hand is important in order to provide dignified care for the deceased while also keeping frontline and health care workers safe. For example, we are seeing refrigerated trailers used as mobile morgues without being equipped with rack and tray systems that can be safely loaded. We can help find solutions to these and other decedent handling issues that arise from COVID-19.”

SourceMopec

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”